publication date: Nov. 16, 2018
In Brief Cornelis Melief receives 2018 ESMO Immuno-Oncology Award
Cornelius Melief received the European Society for Medical Oncology 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer.
The distinction will be officially presented to him at the opening keynote and award lecture of this year’s ESMO Immuno-Oncology Congress in Geneva in December.
“Professor Melief dedicated his career to understanding how the immune system, specifically cytotoxic lymphocytes, interact with cancer, and used this knowledge for the development of new therapeutic cancer vaccine strategies,” said George Coukos, a scientific co-chair of the upcoming congress
After studying virally induced cancer in mice, he is currently involved in clinical trials with synthetic vaccines for the treatment of head and neck as well as cervical cancer associated with the human papilloma virus.
Melief’s work in developing effective immunotherapy for virus induced tumours recently led to the implementation of clinical trials to bring so-called synthetic long peptide vaccines to cancer patients worldwide.
Melief and his team were able to show the clinical effectiveness of these vaccines in treating patients with pre-malignant lesions caused by HPV type 16. They also demonstrated that in patients with cancer, in whom vaccination could not be used effectively on its own and instead should be employed in combination with other therapies.
Among the most promising results … Continue reading Cornelis Melief receives 2018 ESMO Immuno-Oncology Award
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
You will be given immediate access to premium content on the site.
Click here to join.
Bagikan Berita Ini
0 Response to "In Brief Cornelis Melief receives 2018 ESMO Immuno-Oncology Award"
Post a Comment